The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2007, 179, 2330 -2338
Copyright © 2007 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Subramanian, M.
Right arrow Articles by Shaha, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Subramanian, M.
Right arrow Articles by Shaha, C.

Up-Regulation of Bcl-2 through ERK Phosphorylation Is Associated with Human Macrophage Survival in an Estrogen Microenvironment1

Manikandan Subramanian and Chandrima Shaha2

National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Estrogen is a known immunomodulator with pleiotropic effects on macrophage function that partly accounts for the gender bias observed in numerous autoimmune, cardiovascular, and neurodegenerative disorders. The effect of estrogen on the survival of human macrophages is largely unknown, and in this study we demonstrate that 17beta-estradiol (E2) provokes a death response in human THP-1 macrophages by initiating Bax translocation from cytosol to the mitochondria; however, a concomitant up-regulation of Bcl-2 creates a Bax to Bcl-2 ratio favorable for Bcl-2, thus ensuring cell survival. Both Bcl-2 up-regulation and Bax translocation are estrogen receptor-dependent events; however, Bcl-2 augmentation but not Bax translocation is dependent on Ca2+ increase, activation of protein kinase C, and ERK phosphorylation. This estrogen-induced Bcl-2 increase is crucial for the survival of THP-1 macrophages as well as that of human peripheral blood monocyte-derived macrophages, which is evident from E2-induced cell death under small interfering RNA-mediated Bcl-2 knockdown conditions. Hence, this study demonstrates that E2-induced Bcl-2 up-regulation is a homeostatic survival mechanism necessary for the manifestation of immunomodulatory effect of estrogen on human macrophages.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Macrophages express estrogen receptor subtypes {alpha} and beta (1, 2, 3) and are therefore capable of responding to increase in estrogen during the follicular phase of menstrual cycle (4), at the time of exposure from exogenous sources such as phytoestrogens (5), following administration for prophylactic and therapeutic purposes (6), or during accidental exposure to estrogenic chemicals (7, 8). Estrogen affects a variety of macrophage functions; for example, it can reduce accumulation of cholesteryl esters in macrophages (2), stimulate production of NO (9, 10), increase arachidonic acid release (11), regulate activation-related events (2, 12), decrease monocyte adhesion to vasculature (13), enhance macrophage phagocytosis (14), and facilitate Ca2+ influx (10). Some functions are implicated in mediating the gender bias observed in numerous autoimmune (15), cardiovascular (16), and neurodegenerative disorders (17). In addition, estrogen is able to modulate macrophage death, which is of great relevance because macrophage survival or death is crucial for disease pathogenesis (18). However, data available on the influence of the hormone on the macrophage cell death process are contradictory. Existing literature show that macrophage-like U937 cells undergo apoptosis when exposed to estrogen (19), but the same cell type is protected from TNF-{alpha}-induced apoptosis by the hormone (20). According to other reports, estrogen is able to induce apoptosis in undifferentiated U937 monocytes, but macrophages differentiated from these cells are refractory to such effects of estrogen (21). Further examples of cell types in which estrogen is reported to induce cell death include bone macrophages like murine osteoclasts, preosteoclastic FLG 29.1 cell line, and mouse peritoneal macrophages (22, 23, 24, 25).

The apparently paradoxical effect of estrogen on apoptosis in cells of the monocytic lineage could be interpreted to be the result of its ability to differentially modulate antiapoptotic and proapoptotic proteins like the members of the Bcl-2 family that share sequence-homology domains within the group (26). The various proapoptotic and antiapoptotic Bcl-2 family members are able to heterodimerize (26), and their relative concentrations function as a rheostat for the apoptotic program (26). Certain apoptotic stimuli like exposure to NO (27), oxysterol (28), and activation-inducing agents increase macrophage Bcl-2 or other members of the Bcl-2 family of proteins like Bfl-1 (29), but the involvement of Bcl-2 family members in regulating the macrophage death pathway is not completely understood. In the context of tumor development, mechanisms regulating macrophage death are important because these cells constitute a large proportion of the tumor cells and are evidently important for either progression or regression of tumors (30). Survival of macrophages in estrogen microenvironment is relevant especially in the cells populating estrogen target tissues like uteri, breast, brain, and cervix. Also, understanding of the mechanism of macrophage survival under altered Bcl-2 level becomes important in the backdrop of development of Bcl-2 small molecule inhibitors, antisense oligonucleotides, and RNA interference against Bcl-2, which were intended to be used for treatment of resistant carcinoma and some of which are currently in phase I and phase II clinical trials (31, 32, 33, 34, 35). This study was designed to identify the key players that are vital for modulating human macrophage survival under estrogen exposure.

We demonstrate that 17beta-estradiol (E2)3 treatment not only provokes a death response via Bax translocation in macrophages derived from THP-1 human acute monocytic leukemia cells, but also initiates an antiapoptotic response through the up-regulation of Bcl-2 via a Ca2+-dependent ERK-mediated pathway. The importance of E2-induced Bcl-2 up-regulation in macrophage physiology is demonstrated by increased cell death when Bcl-2 is down-regulated through interference with Ca2+ influx, ERK phosphorylation, or small interfering RNA (siRNA)-mediated Bcl-2 mRNA degradation. E2 also induces cell death in human peripheral blood monocyte-derived macrophages (MDM) when Bcl-2 is knocked down with anti-Bcl-2 siRNA.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Materials

E2 (cyclodextrin encapsulated) was obtained from Sigma-Aldrich. ICI 182780, PPT (4,4',4''-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol), and DPN (2,3-bis(4-hydroxyphenyl)-propionitrile) were procured from Tocris Cookson. Primary Ab against Bcl-2 was obtained from Santa Cruz Biotechnology. Abs against phospho-ERK, whole ERK, and phospho-CREB were purchased from StressGen Biotechnologies. Anti-Bax, anti-cytochrome c, and anti-CD14 FITC Abs were purchased from BD Biosciences. Secondary Abs raised in either mice or rabbits conjugated to HRP were obtained from Jackson ImmunoResearch Laboratories. Fluo-3-acetoxymethyl ester (fluo-3-AM) and secondary anti-mouse IgG conjugated to Alexa Fluor 488 were obtained from Molecular Probes. Anti-actin and anti-estrogen receptor C-terminal Abs were from Calbiochem. The Vybrant apoptosis detection system was purchased from Promega. All reagents for Western blotting and ECL development were obtained from Amersham Biosciences. The Bcl-2 siRNA was purchased from Upstate Biotechnology, whereas Cy3-labeled negative control siRNA was procured from Ambion. Transpass R2 transfection reagent was from New England Biolabs. Phenol-red free RPMI 1640 and dextran-coated charcoal stripped FCS was obtained from Biological Industries. Verapamil, PMA, Ca2+ ionophore A 23187, EGTA, PD98059, bisindoleylmaleimide (BIM), Histopaque 1077, and any other chemical used were obtained from Sigma-Aldrich, unless otherwise mentioned.

Peripheral blood monocyte isolation, cell lines, and cell culture

Peripheral blood was collected from healthy male volunteers after obtaining informed consent as per regulations of the Institutional Human Ethics Committee (National Institute of Immunology, New Delhi, India). The PBMC were isolated by density gradient centrifugation using Histopaque 1077 where human whole blood was layered on Histopaque 1077 and centrifuged at 400 x g for 35 min at 25°C. The mononuclear cell population was isolated from the plasma-histopaque interface, and the monocytes were further purified by washing off the nonadherent cells after incubating the total PBMC for 1 h at 37°C. The homogeneity of the obtained population was determined by analyzing immunostaining of the cells with an Ab against monocyte-specific marker CD14-conjugated to FITC. The monocytes were further cultured for 7 days to allow macrophage differentiation. THP-1 cells, a human acute monocytic leukemia cell line obtained from American Type Culture Collection were maintained in RPMI 1640 medium supplemented with 10% FCS. Macrophage differentiation was induced by treatment of THP-1 cells with 10 ng/ml PMA for 36 h, following which cells were maintained in PMA-free medium for 12 h before experimentation. Forty-eight hours before experiment, both cell types were transferred to phenol red-free RPMI 1640 supplemented with 10% dextran-coated charcoal-stripped FCS to remove any extraneous source of estrogen.

Intracellular free Ca2+ assay

Changes in intracellular free Ca2+ concentration were monitored using the Ca2+ binding fluorescent probe fluo-3-AM as previously described (36). Briefly, 106 cells/ml loaded with 0.5 µM fluo-3-AM containing 0.5 µM pluronic acid F-127 were used for different experiments, and free Ca2+ was monitored at an excitation of 480 nm and emission of 520 nm with a Fluostar Optima spectrofluorometer (BMG Technologies). Fluorescence values were converted into absolute intracellular free Ca2+ concentration, using procedures and calculations as previously described (36).

Cell viability assay

For cell viability assays, propidium iodide exclusion by cells and identifying phosphatidylserine exposure by Annexin V-labeling was conducted as previously described (37) using Vybrant apoptosis assay kit. Labeling was analyzed by flow cytometry in which data acquisition was done with a BD LSR flow cytometer equipped with a 488 nm air-cooled argon ion laser. Analysis was done using WinMDI software (Microsoft v.2.8).

RT-PCR

Total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies), and cDNA was synthesized as previously described (36). The specific primers used were the following: Bcl-2 (sense) 5'-GTGGAGGAGCTCTTCAGGGA-3', (antisense) 5'-AGGCACCCAGGGTGATGCCA-3'; and actin (sense) 5'-GTGGGGCGCCCCAGGCACCA-3', (antisense) 5'-CTCCTTAATGTCACGCACGATTTC-3'.

PCR was performed after determining the cycle number in which a linear amplification of serially diluted template could be achieved. The PCR products were then resolved on 1.5% agarose gel and visualized by ethidium bromide staining and quantitated by densitometry.

siRNA transfection

THP-1 macrophages and human peripheral blood MDM were transfected with 15 pmol SMARTpool Bcl-2 siRNA or negative control siRNA using Transpass R2 transfection reagent as per the manufacturer’s instructions. Briefly, Bcl-2 siRNA or negative control siRNA were added to transfection reagent diluted in serum-free medium and incubated for 20 min to allow the formation of transfection complexes. The siRNA transfection complexes were added at a final concentration of 15 pmol to 105 cells/well grown in 24-well plates and incubated for 6 h following which fresh complete medium was added. Transfection efficiency was estimated by observing Cy3 fluorescence of the negative control siRNA with a Nikon TE2000-E fluorescence microscope using a tetramethyl rhodamine filter (530–580 nm). Target protein knockdown was assessed 24 h posttransfection by probing extracts of transfected cells on Western blots with anti-Bcl-2 Ab.

Subcellular fractionation

THP-1 macrophages were harvested and suspended in homogenization buffer (0.5 M sucrose, 10 mM Tris, pH 7.4) containing 1 mM EDTA and protease inhibitor cocktail from Roche Diagnostics with a mixture of various protease inhibitors. Cell lysis was performed by sonication (Sonifier 450; Branson) on ice at 30% duty cycle for a total of 9 cycles. The sonicate was centrifuged at 4000 x g for 10 min to obtain the nuclear pellet. From the resulting supernatant, the mitochondrial fraction was extracted by further centrifugation at 10,000 x g for 10 min (38) in an ultracentrifuge (SW55Ti rotor, optima XL-110K; Beckman Coulter). The postmitochondrial supernatant was further centrifuged at 100,000 x g for 30 min to isolate the microsomal fraction as a pellet and the supernatant obtained was the cytosolic fraction.

SDS-PAGE and Western blot

Whole cell lysates were prepared by mixing cells with lysis buffer (0.125 M Tris, 4% SDS, 20% glycerol, and 10% 2-ME), and the lysates were resolved on 12% SDS-PAGE gel following which they were transferred onto nitrocellulose membrane as previously described (36). The quantitation of protein in cell lysates was conducted with a CBX protein assay kit (G-Biosciences). Western blots were incubated with 5% ECL blocking reagent in 0.05% PBS-Tween 20 for 1 h to block nonspecific binding sites. Primary and secondary Abs were used at appropriate dilutions and reactivity was visualized by ECL using an ECL Western blotting detection system in which membranes were exposed to x-rays for appropriate time periods and subsequently developed before densitometry.

Immunocytochemistry

Formaldehyde (4%) fixed cells were blocked with 3% normal goat serum containing 0.1% saponin at room temperature for 30 min and subsequently incubated with primary Ab at 1/50 dilution for 1 h at 37°C followed by secondary Ab conjugated to Alexa Fluor 488 at 1/100 dilution for 1 h at the same temperature. Subsequently, the cells were washed and resuspended in PBS and analyzed on a BD LSR flow cytometer equipped with an air-cooled 488 nm argon ion laser.

Densitometry

Densitometric measurements for quantitation of signals on immunoblots or ethidium bromide stained agarose gels were performed using a UVP gel documentation instrument, and the acquired data were analyzed with the LabWorks image analysis and acquisition software (v.4.0.0.8.; UVP). At least three Western blots per experiment were quantitated to arrive at the average value of the signal. All measurements were normalized to internal loading controls.

Statistical analysis

Data were analyzed by Student’s t test and values are expressed as mean ± SEM. The values were considered significantly different at p < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
E2 does not affect THP-1 macrophage viability while it increases Bcl-2 levels

To examine whether E2 has any effect on cell survival, THP-1 macrophages were exposed to several doses of the hormone ranging from 1 nM to 1 µM and cell death was estimated at 24 h by propidium iodide (1 µg/ml) exclusion method. No significant cell death could be recorded with any of the doses as compared with vehicle treated (cyclodextrin dissolved in water) controls. Percentage of survival was at the following: vehicle treated, 94 ± 1; 1 nM E2 treatment, 95 ± 2; 10 nM E2 treatment, 96 ± 1; 100 nM E2 treatment, 96 ± 1; and 1 µM E2 treatment, 96 ± 2. Contrary to our findings, some studies show that estrogen causes death in cells of monocytic lineage (19, 21, 22, 23, 24, 25). Arguably, if estrogen is able to induce death in cells of similar lineage, the failure of the hormone to do so in THP-1 macrophages could mean differential regulation of the proapoptotic and antiapoptotic proteins leading to maintenance of viability. A distinct increase in THP-1 macrophage Bcl-2 above the constitutive levels was observed with 10 nM, 100 nM, and 1 µM E2 treatment (Fig. 1A). Because beyond 10 nM there was no appreciable increase in Bcl-2 (Fig. 1A) and 10 nM being within the physiological range (39), all other studies used this dose of E2. With the same dose, a time-dependent augmentation in Bcl-2 protein levels occurred from 1 h onward doubling at 4 h from the constitutive levels at 0 h (Fig. 1B) and was sustained till 72 h (data not shown). Flow cytometric quantitation of Bcl-2 expression in cells of different treatment groups labeled sequentially with anti-Bcl-2 Ab followed by secondary Ab conjugated to Alexa Fluor 488 showed a distinct shift in the mean fluorescence intensity (MFI), which doubled after treatment with E2 as compared with constitutive Bcl-2 levels (vehicle treated) (Fig. 1C). Presence of estrogen receptor antagonist ICI 182780 prevented a shift in fluorophore labeling (Fig. 1C, E2+ICI), and the MFI was similar to vehicle treated controls (Fig. 1C). Therefore, both densitometric quantification of Western blots and flow cytometric analysis demonstrated a 1.5- to 1.9-fold increase in Bcl-2 expression. An increase in Bcl-2 mRNA transcript level after E2 treatment (Fig. 1D) suggested Bcl-2 up-regulation through the genomic route. E2 action on cells could possibly occur through either a receptor-mediated or a receptor-independent pathway (40), therefore to gain insights into which receptor involvement, estrogen receptor antagonists, and agonists were used. Presence of a specific estrogen receptor antagonist ICI 182780 during E2 exposure prevented Bcl-2 up-regulation (Fig. 1E, lane 3). Subtype-specific estrogen receptor agonists, namely DPN, a specific agonist for estrogen receptor-beta (41) and PPT, a specific agonist for estrogen receptor-{alpha} (42) were able to up-regulate Bcl-2 (Fig. 1E, lanes 4 and 5) in the absence of E2. Therefore, data with both agonists and antagonists implicated estrogen receptor involvement. The presence of estrogen receptors was confirmed by flow cytometric analysis of cells stained with anti-estrogen receptor Ab recognizing both estrogen receptors {alpha} and beta that demonstrated expression of estrogen receptors in >95% of THP-1 macrophages (Fig. 1F).


Figure 1
View larger version (22K):
[in this window]
[in a new window]

  		FIGURE 1. Estrogen increases Bcl-2 expression in THP-1 macrophages through an estrogen receptor-dependent mechanism. A, Increase in Bcl-2 levels after 24 h treatment with various doses of E2 is shown on representative immunoblots of THP-1 macrophage lysates probed with anti-Bcl-2 Ab (80 ng/ml). Actin was used as a loading control. B, Time-kinetic analysis of Bcl-2 expression with THP-1 macrophage lysates collected at different time points after 10 nM E2 exposure (0–6 h) showing a time-dependent increase in Bcl-2 levels. Actin was used as a loading control. C, Flow cytometric analysis of Bcl-2 expression as determined by immunostaining of THP-1 macrophages with anti-Bcl-2 mAb (600 ng/ml) after 24 h of treatment of cells with E2 and ICI 182780. Note the distinct shift obtained with E2 as compared with vehicle treated control (VT) and E2 with ICI 182780 (E2+ICI). CSA, control secondary Ab; US, unstained cells. Data shown at bottom are the MFI of the indicated treatment groups and the fold change in Bcl-2 expression (n = 3). *, p < 0.05 for vehicle treated vs E2 treated; #, p < 0.05 for E2 vs E2+ICI. D, RT-PCR analysis for the expression of Bcl-2 at 12 h after treatment with E2 (10 nM) (E2) showing increase in Bcl-2 amplicon (304 bp) with cDNA isolated from THP-1 macrophages (lane 2) as compared with vehicle treated (VT) control (lane 1). Actin RT-PCR served as loading control. E, Immunoblots for Bcl-2 on THP-1 extracts at 24 h after the following treatments: lane 1, vehicle treated (VT); lane 2, 10 nM E2 treatment; lane 3, pretreatment with 1 µM ICI 182780 before E2 treatment; lanes 4 and 5, treatment with 100 nM DPN, an estrogen receptor-beta-specific agonist; and 100 nM PPT, an estrogen receptor-{alpha}-specific agonist. Data shown below immunoblots represent the relative Bcl-2 expression levels normalized to actin as compared with vehicle treated control, calculated by densitometric analysis of multiple immunoblots as detailed in Materials and Methods. Error bars in A, B, and E are ± SEM with n = 3 experiments in duplicate. *, p < 0.05 as compared with vehicle treated; §, p < 0.05 as compared with E2 treated. F, Estrogen receptor expression was analyzed by flow cytometry with THP-1 macrophages immunostained with anti-estrogen receptor Ab reactive to both estrogen receptors {alpha} and beta. The marker represents the percentage population that stain positive for the receptors. CSA, control secondary Ab.

 
Taken together, these data established the capability of E2 to induce an estrogen receptor-dependent increase in Bcl-2 mRNA and protein in human THP-1 macrophages.

E2 induces Bax translocation to the mitochondria in THP-1 macrophage

In many cell systems, the Bax to Bcl-2 ratio serve as a control point upstream of irreversible damage to cellular constituents where Bax translocation to the mitochondria from cytosol occur upon receipt of apoptotic stimuli (43, 44). In THP-1 macrophages, within 4 h of E2 exposure, translocation of Bax from cytosol to the mitochondria occurred (Fig. 2A, lanes 3 and 4). Presence of the estrogen receptor antagonist ICI 182780 during E2 treatment prevented this translocation of Bax (Fig. 2A, lanes 9 and 10). The estrogen receptors beta and {alpha} agonists DPN and PPT, respectively, were able to induce Bax translocation in the absence of E2 (Fig. 2A, lanes 5–8). Over a period of 2 h after E2 treatment, there was a clear increase in the expression of mitochondria associated Bcl-2 and Bax (Fig. 2B), but the ratio of the two proteins remained in favor of Bcl-2 (Fig. 2C). Because of the concomitant increase of Bcl-2 levels the cell survival pathway was favored even after Bax translocation to mitochondria. Taken together, data showed that exposure to E2 induced a death response in the macrophages through a estrogen receptor mediated pathway.


Figure 2
View larger version (29K):
[in this window]
[in a new window]

  		FIGURE 2. Estrogen treatment induces translocation of Bax from cytosol to mitochondria in THP-1 macrophages. A, Immunoblots showing Bax translocation performed on cytosolic and mitochondrial fractions obtained from 4 h lysates of THP-1 macrophage exposed to different treatments as indicated. The purity of the mitochondrial fraction was determined by probing for cytochrome c (Cyt C) using an anti-cytochrome c Ab (500 ng/ml). c, cytosolic fraction; m, mitochondrial fraction. B, Time-kinetic analysis of Bcl-2 up-regulation and Bax translocation through immunoblotting of cytosolic and mitochondrial fractions of THP-1 macrophages with anti-Bcl-2 (80 ng/ml) and anti-Bax Abs (500 ng/ml). Silver-stained gel (top) shows profiles of mitochondrial and cytosolic fractions with equal amounts of protein loaded. Immunoblot analysis (bottom three panels) is shown of Bcl-2, Bax, and cytochrome c in cytosol and mitochondrial fraction of cells after 10 nM E2 treatment collected at indicated time points. C, Data represents absolute values of Bcl-2 and Bax and their ratio at various time intervals after E2 treatment as determined by densitometric analysis of specific immunoreactive bands on blots, representatives of which are shown in B. Data are representative of three independent experiments.

 
Bcl-2 expression is dependent on intracellular Ca2+ concentration

There is a close relationship between Bcl-2 expression and intracellular Ca2+ changes because although Bcl-2 can regulate release of Ca2+ from the endoplasmic reticulum stores (45), Ca2+ is reported to be able to regulate Bcl-2 expression through the ERK signaling pathway (46). Intracellular Ca2+ levels doubled within a minute after addition of E2 (Fig. 3A) and a second peak of Ca2+ increase occurred without any further addition of E2 at around 90 min, and this level of ~90 nM was maintained till 140 min, the time point at which the last measurement was made (Fig. 3A). Presence of the ICI 182780 (Fig. 3A, ICI+E2) could attenuate the increase in Ca2+ (Fig. 3A), indicating that Ca2+ modulation was an estrogen receptor-dependent phenomenon. The source of Ca2+ that contributed to the intracellular increase was of extracellular origin because presence of EGTA (Fig. 3A, E2+EGTA) during estradiol treatment prevented both Ca2+ peaks (Fig. 3A). To determine the route of Ca2+ influx, we used voltage gated Ca2+ channel blockers like pimozide for T-type channels (47) and verapamil for L-type channels (48) and Na+/Ca2+ exchange blockers like benzamil (49) and bepridil (50). Pimozide, bepridil or benzamil could not prevent Ca2+ influx (data not shown), but verapamil was able to reduce both Ca2+ peaks when added at two different time points, one before addition of E2 (Fig. 3A, V1) and another just before the second increase of Ca2+ (Fig. 3A, V2), suggesting the involvement of L-type Ca2+ channels. Microscopically, a clear increase in labeling with Ca2+ binding fluorescent dye fluo-3-AM was evident in the E2 treatment group (Fig. 3B, iv) as compared with vehicle treated controls (Fig. 3B, ii). Cells treated with E2 in the presence of ICI 182780 (Fig. 3B, vi) and verapamil (Fig. 3B, viii) did not show any detectable increase in Ca2+ levels in the cells, the constitutive levels of Ca2+ being nondetectable by fluorescence microscopy. To establish whether this increase in Ca2+ was related to Bcl-2 expression, verapamil was used to prevent Ca2+ entry after E2 treatment. Verapamil added before initiation of E2 treatment (Fig. 3C, V1+E2) inhibited Bcl-2 increase significantly as compared with that induced by E2 alone (Fig. 3C, E2). However, addition of verapamil just before the second peak of Ca2+ (Fig. 3C, V2+E2) could not produce statistically significant inhibition of Bcl-2 levels. Collectively, these experiment established that E2 was able to induce a biphasic Ca2+ increase through L-type Ca2+ channels and the first peak of Ca2+ was linked to Bcl-2 increase.


Figure 3
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 3. E2-induced Ca2+ release regulates Bcl-2 expression. A, Intracellular free Ca2+ was measured using 0.5 µM Ca2+ binding dye fluo-3-AM to label 106 cells/ml of THP-1 macrophages, and 10 nM E2 was added in the presence or absence of 20 µM verapamil added 10 min before (E2+V1) or 20 min after (E2+V2) the hormone addition, or in the presence of 1 µM ICI 182780 (E2+ICI), or 2 mM EGTA (E2+EGTA) and monitored over 150 min. VT, vehicle treated. B, Fluo-3-AM-labeled THP-1 macrophages showing intracellular Ca2+; vehicle treated (ii), 10 nM E2 treatment (iv), 10 nM E2 treatment along with 1 µM ICI 182780 (vi) and 10 nM E2 treatment plus 20 µM verapamil (viii). Panels i, iii, v, and vii represent the respective phase contrast images. Scale bar represents 10 µm. C, The effect of 20 µM verapamil on THP-1 macrophage Bcl-2 levels. Verapamil treatment before addition of E2 (V1+E2), verapamil treatment 20 min after E2 addition (V2+E2), E2-treated cells (E2), and vehicle treated control (VT) show the ability of verapamil to reduce E2-induced Bcl-2 levels. Data represent the relative Bcl-2 expression levels normalized to actin as compared with vehicle treated control, calculated by densitometric analysis of multiple immunoblots as detailed in Materials and Methods. Error bars are ± SEM with n = 3 experiments in duplicate. *, p < 0.05 as compared with vehicle treated control, #, p < 0.05, ET vs V1+ET.

 
ERK phosphorylation regulates Bcl-2 expression

Prior knowledge on the effects of Ca2+ on ERK phosphorylation (46) prompted us to check the effect of E2 on ERK. ERK phosphorylation occurred within 5 min of E2 exposure (Fig. 4A, lane 2) and was dependent on intracellular Ca2+ levels because verapamil could prevent ERK phosphorylation (Fig. 4A, lane 3). To check upstream events to ERK phosphorylation, BIM, a protein kinase C (PKC) inhibitor, was used at 1 µM concentration (51) and it was able to inhibit ERK phosphorylation (Fig. 4B, lane 4). PD98059, a selective pharmacological antagonist that inhibits MEK-1, which phosphorylates and activates ERK, was able to partially inhibit estrogen-induced Bcl-2 increase (Fig. 4C, lanes 3 and 4) when used at a dose of 25 µM (52). Therefore, a link between PKC pathway, phosphorylation of ERK, and Bcl-2 increase could be established. Downstream to ERK phosphorylation, CREB phosphorylation occurred (Fig. 4D), suggesting that possibly CREB could mediate ERK-induced effects and that ERK consequently acts as a prosurvival protein inducing Bcl-2 increase. Because along with Bcl-2 increase, there was a concomitant translocation of Bax, it was of interest to see whether the PKC-ERK pathway was involved in Bax translocation. E2-induced Bax translocation (Fig. 4E, lanes 3 and 4) could not be prevented by either verapamil (Fig. 4E, lanes 5 and 6) or PD98059 (Fig. 4E, lanes 7 and 8), showing that Bax translocation was not dependent on Ca2+ or ERK phosphorylation. Because the primary function of Bax is to facilitate cytochrome c release into the cytosol from the mitochondria, both mitochondrial and cytosolic fractions of E2-treated and untreated cells in the presence of verapamil and PD98059 were checked. In both cases, at around 12 h, a distinct cytochrome c release into the cytosol was observed that was not visible at 2 h (Fig. 4E). Collectively, these data suggest that E2 mediates increase in Bcl-2 levels via the Ca2+-PKC-ERK signaling pathway, but Bax translocation was independent of this signaling cascade.


Figure 4
View larger version (26K):
[in this window]
[in a new window]

  		FIGURE 4. E2 induces up-regulation of Bcl-2 by a Ca2+-dependent ERK phosphorylation mechanism. A, THP-1 macrophages were preincubated with 20 µM verapamil for 10 min before a 5 min treatment with 10 nM E2. Whole cell lysates were prepared, and Western blots were probed using specific Abs against phosphorylated ERK1/2 (1/1000) or whole ERK1/2 (900 ng/ml). Blot shows distinct ERK phosphorylation on E2 treatment (lane 2). Cells treated with PMA (100 nM) were used as a positive control for ERK phosphorylation. B, THP-1 macrophages were preincubated with 1 µM BIM, a specific PKC inhibitor for 30 min before a 5 min treatment with 10 nM E2. Western blots of whole cell lysates prepared from cells collected at 5 min after E2 treatment were probed using specific Abs against phosphorylated ERK1/2 or total ERK1/2. DMSO treatment (lane 2) was used as a control as BIM was dissolved in DMSO. Cells treated with PMA (100 nM) were used as a positive control. C, THP-1 cells were preincubated with 25 µM PD98059 for 10 min or 1 µM BIM for 30 min before treatment with E2 for 6 h. A clear reduction in Bcl-2 levels was observed with BIM (lane 3) and PD (lane 4) on Western blots. Actin was used as loading control. D, CREB phosphorylation (pCREB) was analyzed by Western blotting of extracts obtained from cells treated with or without 10 nM E2 for 15–60 min as indicated. Data in A–D represent densitometric analysis. Error bars are ± SEM with n = 3 experiments in duplicate. *, p < 0.05, vehicle treated vs E2 treated; #, p < 0.05, groups compared with E2 treatment. E, Silver-stained gel (top) with equal loading of mitochondrial (m) and cytosolic (c) fractions representing protein loading for blots. The panels below represent immunoblots probed with anti-Bax (500 ng/ml) and anti-cytochrome c (500 ng/ml) Abs showing blots at 2 h after cells were treated with only E2 (lanes 3 and 4) or with 20 µM verapamil and E2 (ver+E2) (lanes 5 and 6) or 25 µM PD98059 with E2 (PD+E2) (lanes 7 and 8). Cytochrome c release at 12 h is shown for the same groups.

 
E2 does not affect human peripheral blood MDM viability while it up-regulates Bcl-2

In view of the results obtained with THP-1 macrophages, we used human peripheral blood MDM as a cellular system to validate the effects of E2 in primary cells. Exposure of human peripheral blood MDM to E2 did not induce any loss of viability. The percentage of survival was as follows: vehicle treated, 95 ± 2; 1 nM E2 treatment, 93 ± 3; 10 nM E2 treatment, 95 ± 2; 100 nM E2 treatment, 96 ± 1; and 1 µM E2 treatment, 95 ± 1. Considering our results with THP-1 macrophage, we checked Bcl-2 levels and >1.5 fold up-regulation of Bcl-2 protein was observed after E2 treatment in human peripheral blood MDM (Fig. 5A, lane 2) as compared with constitutive Bcl-2 levels (Fig. 5A, lane 1) and presence of estrogen receptor antagonist ICI 182780 prevented Bcl-2 increase from constitutive levels by 75% (Fig. 5A, lane 3). To further confirm action through estrogen receptors and elucidate the receptor subtypes involved, DPN and PPT were used and both treatments increased Bcl-2 expression (Fig. 5A, lanes 4 and 5) in the absence of E2, suggesting involvement of both estrogen receptors beta and {alpha}. Also, to directly demonstrate the presence of estrogen receptors in human peripheral blood MDM, immunocytochemistry was performed with an Ab that recognizes both estrogen receptors {alpha} and beta and analyzed by flow cytometry, which showed that >95% of human peripheral blood MDM express estrogen receptors (Fig. 5B).


Figure 5
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 5. E2 induces Bcl-2 up-regulation in human MDM. A, Human MDM were treated with 10 nM E2 only (E2), E2 with 1 µM ICI 182780 (ICI+E2), or 100 nM DPN or PPT in the absence of E2, and whole cell extracts were probed for Bcl-2 expression by Western blotting. Actin was used as loading control. Data represent relative Bcl-2 expression levels normalized to actin as compared with vehicle treated control, calculated by densitometric analyses of multiple immunoblots as detailed in Materials and Methods. Error bars are ± SEM from n = 3 experiments in duplicate. *, p < 0.05 for lane 1 vs 2; #, p < 0.05, lane 2 vs 3. B, Estrogen receptor expression was analyzed by flow cytometry on human peripheral blood MDM immunostained with anti-estrogen receptor Ab reactive to both estrogen receptors {alpha} and beta. The marker represents the percentage population that stain positive for the receptors. CSA, control secondary Ab; US, unstained cells.

 
E2 induces THP-1 macrophage cell death in Bcl-2 knockdown conditions

Because E2 initiated a concomitant translocation of Bax along with Bcl-2 increase, the question was how the cells would behave under Bcl-2 knockdown conditions. For this experiment, several routes of Bcl-2 inhibition in the presence of E2 were exploited. L-type Ca2+ channel blocker verapamil, PKC inhibitor BIM, and MEK inhibitor PD98059 were used to reduce Bcl-2 levels and cell fate was followed. Because the described treatments could have global effects affecting other pathways, Bcl-2 inhibition through the use of siRNA against Bcl-2 was used during E2 treatment. Fig. 6, A and B, demonstrates Bcl-2 decrease in the presence of Bcl-2 siRNA in THP-1 macrophages and human peripheral blood MDM, respectively. A 60% down-regulation of constitutive Bcl-2 in THP-1 macrophages (Fig. 6A, second lane) as compared with cells transfected with negative control siRNA (Fig. 6A, first lane) could be achieved. The transfection efficiency was ~95% estimated by fluorescence microscopic analysis of Cy3-labeled negative control siRNA. In E2-treated THP-1 macrophages, Bcl-2 up-regulation could be significantly knocked down with siRNA against Bcl-2 (Fig. 6A, last lane) as compared with E2 treatment in the presence of negative control siRNA (Fig. 6A, third lane). In human peripheral blood MDM, ~30% down-regulation of constitutive Bcl-2 was achieved with Bcl-2 siRNA (Fig. 6B, second lane) as compared with cells treated with negative control siRNA (Fig. 6B, first lane). The transfection efficiency of siRNA was ~95% as detected by observing fluorescence of Cy3-labeled negative control siRNA. As observed in THP-1 macrophages, siRNA against Bcl-2 was able to knockdown E2 induced Bcl-2 up-regulation significantly in human peripheral blood MDM (Fig. 6B, fourth lane) as well as compared with E2 treatment in the presence of negative control siRNA (Fig. 6B, third lane).


Figure 6
View larger version (28K):
[in this window]
[in a new window]

  		FIGURE 6. Inhibition of E2-induced Bcl-2 up-regulation results in cell death. The Bcl-2 siRNA-mediated Bcl-2 knockdown efficiency is shown on Western blots of extracts of THP-1 macrophages (A) or human peripheral blood MDM (B) treated with 10 nM E2 or without E2 and probed with mouse monoclonal anti-Bcl-2 Ab (80 ng/ml). Negative control siRNA was used as a target gene knockdown specificity control. Data represent the relative Bcl-2 expression levels normalized to actin as compared with vehicle treated control, calculated by densitometric analyses of multiple immunoblots as detailed in Materials and Methods. Error bars are ± SEM with n = 3 experiments in duplicate. *, p < 0.05 first lane vs second; #, p < 0.05, first lane vs third; §, p < 0.05, third lane vs fourth. C, THP-1 macrophages were preincubated with 20 µM verapamil or 25 µM PD98059 for 10 min or 1 µM BIM for 30 min before treatment with 10 nM E2 for 12 h. Cell death was analyzed by fluorescence microscopy using propidium iodide (1 µg/ml) staining. Data are representative of three independent experiments. Error bars are ± SEM with n = 3 experiments. *, p < 0.05 for E2 vs Ver+E2, BIM+E2, and PD+E2. D, Flow cytometric analysis of THP-1 viability by simultaneous Annexin V and propidium iodide staining of cells transfected with negative control siRNA and treated with (ii) or without (i) E2, Bcl-2 siRNA treated without (iii) or with 10 nM E2 for 2 h (iv), 4 h (v), and 6 h (vi). E, Flow cytometric analysis of THP-1 viability by simultaneous Annexin V and propidium iodide staining of cells transfected with negative control siRNA treated with (ii) or without (i) E2, Bcl-2 siRNA treated without (iii) or with 10 nM E2 for 2 h (iv), 6 h (v), or in the presence of ICI 182780 (vi). The y-axis represents propidium iodide labeling and the x-axis represents Annexin V labeling. The percentage shown represents cells analyzed that lie within each quadrant.

 
Analysis of viability in the presence of agents that inhibited Bcl-2 increase, namely verapamil, BIM, or PD98059, during E2 treatment showed a significant increase in cell death as compared with only E2 group (Fig. 6C). When the number of THP-1 macrophages entering the death pathway after estrogen exposure was estimated in a siRNA-mediated Bcl-2 knockdown condition by calculating cells showing phosphatidylserine exposure, nuclear propidium iodide staining, or both, then ~53%, 63%, and 82% of the cells tested positive at 2, 4, and 6 h (Fig. 6D, iv–vi), respectively, as compared with 1% in the absence of estrogen exposure (Fig. 6D, iii). Human peripheral blood MDM behaved similarly, and the number of human peripheral blood MDM entering the death pathway after estrogen exposure was 40% and 57% at 2 and 6 h (Fig. 6E, iv and v), respectively, as compared with 10% in the absence of estrogen exposure (Fig. 6E, iii). ICI 182780 could prevent cell death after E2 exposure (Fig. 6E, vi). This result clearly showed that Bcl-2 knockdown makes the THP-1 macrophages and human peripheral blood MDM susceptible to the death-inducing effects of E2.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The ability of macrophages to respond to estrogen plays an incisive role in macrophage function (9, 10, 11, 12, 13, 14), and in this study we establish the mechanism by which estrogen regulates the macrophage mitochondrial death pathway. Our report illustrates the function of two Bcl-2 family members with disparate biological properties, namely Bax and Bcl-2 (26) in regulating estrogen-induced effects on macrophage survival. The ability of estrogen to influence macrophages would depend on the presence of functional receptors unless the hormone acts through a receptor independent pathway (40). Because both THP-1 macrophages and human peripheral blood MDM contained functional receptors proven by the ability of estrogen agonists to mimic E2 action on Bcl-2 and Bax and estrogen antagonists to prevent such action, the cells were therefore competent to respond to E2 via receptors. Clearly, the effect of E2 on Bcl-2 was a genomic effect mediated through a PKC-ERK signaling pathway because there was an actual increase in Bcl-2 transcript level. It was unlikely that estrogen responsive elements in bcl-2 gene (53) were directly involved in responding to E2 because interference with the events of Ca2+ influx, PKC activation, and ERK phosphorylation could prevent E2 induced Bcl-2 increase. Changes in cellular Ca2+ induced by any stimuli are an important event for a cell in terms of its survival (54). There is a close relationship between Bcl-2 and Ca2+ because although Ca2+ can mediate Bcl-2 increase, Bcl-2 can also regulate cellular Ca2+ through manipulation of endoplasmic reticulum Ca2+ stores (45). Bcl-2-induced modulation of Ca2+ was excluded by the inability of siRNA-mediated Bcl-2 knockdown to affect E2-induced Ca2+ elevation (data not shown), but experiments with L-type Ca2+ channel blocker that resulted in a reduction of Ca2+ and, consequently, inhibited Bcl-2 increase suggested a situation like hippocampal neurons in which estrogen activates rapid Ca2+ influx (55). Interestingly, there were two peaks of Ca2+ increase both of which could be inhibited by verapamil, but although inhibition of the first resulted in inhibition of Bcl-2, lowering of the second peak did not prevent Bcl-2 increase, suggesting that involvement of the second peak of Ca2+ in Bcl-2 expression is unlikely and increased Ca2+ at that point in time could be serving some other purpose.

The augmentation of Bcl-2 levels by E2 in both THP-1 macrophages and human peripheral blood MDM suggested the creation of a favorable condition for the cells to survive. Similar instances of estrogen-induced Bcl-2 up-regulation by ~1.3-fold have been demonstrated to protect B cells from BCR-mediated apoptosis (56). Increase in Bcl-2 under estrogen exposure is also observed in neurons (57) and MCF-7 breast cancer cells (58). Although Bcl-2 must ensure cell viability as demanded by certain conditions of stress, cell death is facilitated by translocation of Bax from cytosol to the mitochondria (59). In the mitochondria, Bax could either be overwhelmed by the amount of Bcl-2 present and the equilibrium will shift to Bcl-2 ensuring survival or in low Bcl-2 conditions Bax will prevail and facilitate release of cytochrome c ensuring death (59). As Bax translocation was independent of Ca2+ increase and activation of the PKC pathway, this provided us with an opportunity to investigate Bcl-2 function without interfering with Bax translocation. The crucial role of estrogen induced Bcl-2 increase was obvious from experiments in which L-type Ca2+ channel blocker verapamil restricted Ca2+ influx, and the consequent inhibition of the PKC pathway prevented ERK phosphorylation resulting in Bcl-2 decrease but did not inhibit Bax translocation as a result of which cell death ensued. Although the above data confirmed the importance of the altered Bax/Bcl-2 level for survival, both PKC and ERK activity could involve other pathways as well. Therefore, to unequivocally prove the involvement of Bcl-2 in macrophage survival at the time of estrogen exposure, we used Bcl-2 siRNA to knockdown Bcl-2 levels during E2 treatment, and our studies establish that Bcl-2 up-regulation is an absolute requirement for macrophage survival in the presence of estrogen. The reduced number of late apoptotic cells observed in THP-1 macrophages as compared with human peripheral blood MDM could be attributed to higher expression of antiapoptotic proteins in THP-1 (60) due to its leukemic nature.

Clearly, E2 shows two distinct set of effects. Although increase in Ca2+ leads to ERK phosphorylation resulting in an increase in Bcl-2, which is an antiapoptotic signal, a distinct proapoptotic signal in the form of translocation of Bax from cytosol to mitochondria was generated by the Ca2+ signaling-independent but estrogen receptor-dependent pathway (Fig. 7). Therefore, in macrophages, estrogen shows a dichotomous effect and depending on other factors that could influence Bax or Bcl-2 proteins in a given circumstance, a survival or a death pathway would be chosen.


Figure 7
View larger version (33K):
[in this window]
[in a new window]

  		FIGURE 7. Schematic showing intracellular signaling pathways involved in estrogen action on human macrophages. The model diagram illustrates the dichotomous effect of estrogen on human macrophage survival. The pathway highlighted in green represents the antiapoptotic signals and those highlighted in red represent the proapoptotic signals activated by estrogen. Estrogen-induced increase in Ca2+ leads to ERK phosphorylation and consequently CREB phosphorylation, resulting in an increase in Bcl-2. Translocation of Bax from cytosol to mitochondria is Ca2+ signaling-independent but estrogen receptor-dependent. Interference with Bcl-2 increase through inhibition of Ca2+ (verapamil), PKC (BIM), phosphorylation of ERK (PD98059), and Bcl-2 mRNA degradation via Bcl-2 siRNA leads to cell death in presence of estrogen due to elevated levels of Bax.

 
How might our findings be integrated into a model of macrophage behavior in high estrogen microenvironments? From a pathological point of view, there are two possible scenarios in which this estrogen mediated cell survival could be of relevance. Optimally, macrophage survival at tumor or inflammatory sites during chemotherapy is essential during the orderly process of cell death to restrict harm to host tissues (61). Our report provides a new insight into macrophage function in response to estrogen where the hormone is able to generate a cytoprotective response in macrophages through manipulation of the Bcl-2 proteins. This function will be crucial under conditions of Bcl-2 down-regulation (31, 32, 33, 34, 35) when macrophage population will be depleted if Bcl-2 knockdown is attempted in tumors of estrogen targets. On the contrary, in many tumors, tumor-associated macrophages play a protumorigenic role by secreting growth factors and angiogenic factors and current antitumor strategy includes targeted destruction of these cells in which case macrophage killing through Bcl-2 down-regulation would be beneficial for tumor therapy. From a physiological point of view, estrogen-induced Bcl-2 up-regulation is obligate for human macrophage survival and hence necessary for the manifestation of the immunomodulatory effects of estrogen on macrophages.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from the Department of Biotechnology, New Delhi, India. Back

2 Address correspondence and reprint requests to Dr. Chandrima Shaha, National Institute of Immunology, Aruna Asaf Ali Marg, 110067 New Delhi, India. E-mail address: cshaha{at}nii.res.in Back

3 Abbreviations used in this paper: E2, 17beta-estradiol; siRNA, small interfering RNA; MFI, mean fluorescence intensity; fluo-3-AM, fluo-3 acetoxymethyl ester; BIM, bisindoleylmaleimide; MDM, monocyte-derived macrophage; PKC, protein kinase C. Back

Received for publication May 30, 2007. Accepted for publication June 1, 2007.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Cutolo, M., B. Villaggio, A. Bisso, A. Sulli, D. Coviello, J. M. Dayer. 2001. Presence of estrogen receptors in human myeloid monocytic cells (THP-1 cell line). Eur. Cytokine. Netw. 12: 368-372. [Medline]
  2. Kramer, P. R., S. Wray. 2002. 17beta-estradiol regulates expression of genes that function in macrophage activation and cholesterol homeostasis. J. Steroid Biochem. Mol. Biol. 81: 203-216. [Medline]
  3. Phiel, K. L., R. A. Henderson, S. J. Adelman, M. M. Elloso. 2005. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol. Lett. 97: 107-113. [Medline]
  4. Petrovska, M., D. G. Dimitrov, S. D. Michael. 1996. Quantitative changes in macrophage distribution in normal mouse ovary over the course of the estrous cycle examined with an image analysis system. Am. J. Reprod. Immunol. 36: 175-183. [Medline]
  5. Owen, A. J., M. Abbey. 2004. The effect of estrogens and phytoestrogenic lignans on macrophage uptake of atherogenic lipoproteins. Biofactors 20: 119-127. [Medline]
  6. Miller, A. P., Y. F. Chen, D. Xing, W. Feng, S. Oparil. 2003. Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 42: 657-663. [Abstract/Free Full Text]
  7. Bowers, J. L., V. V. Tyulmenkov, S. C. Jernigan, C. M. Klinge. 2000. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors {alpha} and beta. Endocrinology 141: 3657-3667. [Abstract/Free Full Text]
  8. Kuiper, G. G., J. G. Lemmen, B. Carlsson, J. C. Corton, S. H. Safe, P. T. van der Saag, B. B. van der, J. A. Gustafsson. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139: 4252-4263. [Abstract/Free Full Text]
  9. Stefano, G. B., V. Prevot, J. C. Beauvillain, C. Fimiani, I. Welters, P. Cadet, C. Breton, J. Pestel, M. Salzet, T. V. Bilfinger. 1999. Estradiol coupling to human monocyte nitric oxide release is dependent on intracellular calcium transients: evidence for an estrogen surface receptor. J. Immunol. 163: 3758-3763. [Abstract/Free Full Text]
  10. Azenabor, A. A., S. Yang, G. Job, O. O. Adedokun. 2004. Expression of iNOS gene in macrophages stimulated with 17beta-estradiol is regulated by free intracellular Ca2+. Biochem. Cell Biol. 82: 381-390. [Medline]
  11. Lu, B., Y. J. Jiang, P. C. Choy. 2004. 17beta-Estradiol enhances prostaglandin E2 production in human U937-derived macrophages. Mol. Cell Biochem. 262: 101-110. [Medline]
  12. Vegeto, E., S. Ghisletti, C. Meda, S. Etteri, S. Belcredito, A. Maggi. 2004. Regulation of the lipopolysaccharide signal transduction pathway by 17beta-estradiol in macrophage cells. J. Steroid Biochem. Mol. Biol. 91: 59-66. [Medline]
  13. Nathan, L., S. Pervin, R. Singh, M. Rosenfeld, G. Chaudhuri. 1999. Estradiol inhibits leukocyte adhesion and transendothelial migration in rabbits in vivo: possible mechanisms for gender differences in atherosclerosis. Circ. Res. 85: 377-385. [Abstract/Free Full Text]
  14. Chao, T. C., A. Phuangsab, P. J. Van Alten, R. J. Walter. 1996. Steroid sex hormones and macrophage function: regulation of chemiluminescence and phagocytosis. Am. J. Reprod. Immunol. 35: 106-113. [Medline]
  15. Cutolo, M.. 1999. Macrophages as effectors of the immunoendocrinologic interactions in autoimmune rheumatic diseases. Ann. N. Y. Acad. Sci. 876: 32-41. [Medline]
  16. McCrohon, J. A., S. Nakhla, W. Jessup, K. K. Stanley, D. S. Celermajer. 1999. Estrogen and progesterone reduce lipid accumulation in human monocyte-derived macrophages: a sex-specific effect. Circulation 100: 2319-2325. [Abstract/Free Full Text]
  17. Li, R., Y. Shen, L. B. Yang, L. F. Lue, C. Finch, J. Rogers. 2000. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J. Neurochem. 75: 1447-1454. [Medline]
  18. Lewis, C. E., J. O’D. McGee. 1992. The Macrophage Oxford University Press, New York, NY.
  19. Carruba, G., P. D’Agostino, M. Miele, M. Calabro, C. Barbera, G. D. Bella, S. Milano, V. Ferlazzo, R. Caruso, M. L. Rosa, et al 2003. Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J. Cell Biochem. 90: 187-196. [Medline]
  20. Vegeto, E., G. Pollio, C. Pellicciari, A. Maggi. 1999. Estrogen and progesterone induction of survival of monoblastoid cells undergoing TNF-{alpha}-induced apoptosis. FASEB J. 13: 793-803. [Abstract/Free Full Text]
  21. Mor, G., E. Sapi, V. M. Abrahams, T. Rutherford, J. Song, X. Y. Hao, S. Muzaffar, F. Kohen. 2003. Interaction of the estrogen receptors with the Fas ligand promoter in human monocytes. J. Immunol. 170: 114-122. [Abstract/Free Full Text]
  22. Saintier, D., V. Khanine, B. Uzan, H. K. Ea, M. C. de Vernejoul, M. E. Cohen-Solal. 2006. Estradiol inhibits adhesion and promotes apoptosis in murine osteoclasts in vitro. J. Steroid Biochem. Mol. Biol. 99: 165-173. [Medline]
  23. Kameda, T., H. Mano, T. Yuasa, Y. Mori, K. Miyazawa, M. Shiokawa, Y. Nakamaru, E. Hiroi, K. Hiura, A. Kameda, et al 1997. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J. Exp. Med. 186: 489-495. [Abstract/Free Full Text]
  24. Zecchi-Orlandini, S., L. Formigli, A. Tani, S. Benvenuti, G. Fiorelli, L. Papucci, S. Capaccioli, G. E. Orlandini, M. L. Brandi. 1999. 17beta-Estradiol induces apoptosis in the preosteoclastic FLG 29.1 cell line. Biochem. Biophys. Res. Commun. 255: 680-685. [Medline]
  25. Zhang, X. W., X. L. Niu, Z. G. Guo. 1997. Estrogens induce apoptosis in mouse peritoneal macrophages. Zhongguo. Yao. Li. Xue. Bao. 18: 267-270. [Medline]
  26. Chao, D. T., S. J. Korsmeyer. 1998. Bcl-2 family: regulators of cell death. Annu. Rev. Immunol. 16: 395-419. [Medline]
  27. Messmer, U. K., U. K. Reed, B. Brune. 1996. Bcl-2 protects macrophages from nitric oxide-induced apoptosis. J. Biol. Chem. 271: 20192-20197. [Abstract/Free Full Text]
  28. Harada, K., S. Ishibashi, T. Miyashita, J. Osuga, H. Yagyu, K. Ohashi, Y. Yazaki, N. Yamada. 1997. Bcl-2 protein inhibits oxysterol-induced apoptosis through suppressing CPP32-mediated pathway. FEBS Lett. 411: 63-66. [Medline]
  29. Perera, L. P., T. A. Waldmann. 1998. Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. Proc. Natl. Acad. Sci. USA 95: 14308-14313. [Abstract/Free Full Text]
  30. Lewis, C. E., J. W. Pollard. 2006. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66: 605-612. [Abstract/Free Full Text]
  31. Garber, K.. 2005. New apoptosis drugs face critical test. Nat. Biotechnol. 23: 409-411. [Medline]
  32. Waters, J. S., A. Webb, D. Cunningham, P. A. Clarke, F. Raynaud, F. di Stefano, F. E. Cotter. 2000. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J. Clin. Oncol. 18: 1812-1823. [Abstract/Free Full Text]
  33. Morris, M. J., W. P. Tong, C. Cordon-Cardo, M. Drobnjak, W. K. Kelly, S. F. Slovin, K. L. Terry, K. Siedlecki, P. Swanson, M. Rafi, et al 2002. Phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin. Cancer Res. 8: 679-683. [Abstract/Free Full Text]
  34. Rudin, C. M., M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, E. E. Vokes. 2004. Phase I study of G3139, a Bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J. Clin. Oncol. 22: 1110-1117. [Abstract/Free Full Text]
  35. Devi, G. R.. 2006. siRNA-based approaches in cancer therapy. Cancer Gene Ther. 13: 819-829. [Medline]
  36. Mishra, D. P., R. Pal, C. Shaha. 2006. Changes in cytosolic Ca2+ levels regulate Bcl-xS and Bcl-xL expression in spermatogenic cells during apoptotic death. J. Biol. Chem. 281: 2133-2143. [Abstract/Free Full Text]
  37. Mishra, D. P., C. Shaha. 2005. Estrogen-induced spermatogenic cell apoptosis occurs via the mitochondrial pathway: role of superoxide and nitric oxide. J. Biol. Chem. 280: 6181-6196. [Abstract/Free Full Text]
  38. Rieger, M. A., R. Ebner, D. R. Bell, A. Kiessling, J. Rohayem, M. Schmitz, A. Temme, E. P. Rieber, B. Weigle. 2004. Identification of a novel mammary-restricted cytochrome P450, CYP4Z1, with overexpression in breast carcinoma. Cancer Res. 64: 2357-2364. [Abstract/Free Full Text]
  39. Tam, S. P., T. K. Archer, R. G. Deeley. 1985. Effects of estrogen on apolipoprotein secretion by the human hepatocarcinoma cell line, HepG2. J. Biol. Chem. 260: 1670-1675. [Abstract/Free Full Text]
  40. Kelly, M. J., E. J. Wagner. 1999. Estrogen modulation of G-protein-coupled receptors. Trends Endocrinol. Metab. 10: 369-374. [Medline]
  41. Kraichely, D. M., J. Sun, J. A. Katzenellenbogen, B. S. Katzenellenbogen. 2000. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-{alpha} and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology 141: 3534-3545. [Abstract/Free Full Text]
  42. Meyers, M. J., J. Sun, K. E. Carlson, G. A. Marriner, B. S. Katzenellenbogen, J. A. Katzenellenbogen. 2001. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 44: 4230-4251. [Medline]
  43. Martinou, J. C., D. R. Green. 2001. Breaking the mitochondrial barrier. Nat. Rev. Mol. Cell Biol. 2: 63-67. [Medline]
  44. Oltvai, Z. N., C. L. Milliman, S. J. Korsmeyer. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619. [Medline]
  45. Lam, M., G. Dubyak, L. Chen, G. Nunez, R. L. Miesfeld, C. W. Distelhorst. 1994. Evidence that Bcl-2 represses apoptosis by regulating endoplasmic reticulum-associated Ca2+ fluxes. Proc. Natl. Acad. Sci. USA 91: 6569-6573. [Abstract/Free Full Text]
  46. Nilsen, J., B. R. Diaz. 2003. Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. Proc. Natl. Acad. Sci. USA 100: 2842-2847. [Abstract/Free Full Text]
  47. Santi, C. M., F. S. Cayabyab, K. G. Sutton, J. E. McRory, J. Mezeyova, K. S. Hamming, D. Parker, A. Stea, T. P. Snutch. 2002. Differential inhibition of T-type calcium channels by neuroleptics. J. Neurosci. 22: 396-403. [Abstract/Free Full Text]
  48. Lacinova, L., A. Welling, E. Bosse, P. Ruth, V. Flockerzi, F. Hofmann. 1995. Interaction of Ro 40–5967 and verapamil with the stably expressed {alpha}1-subunit of the cardiac L-type calcium channel. J. Pharmacol. Exp. Ther. 274: 54-63. [Abstract/Free Full Text]
  49. Pierce, G. N., W. C. Cole, K. Liu, H. Massaeli, T. G. Maddaford, Y. J. Chen, C. D. McPherson, S. Jain, D. Sontag. 1993. Modulation of cardiac performance by amiloride and several selected derivatives of amiloride. J. Pharmacol. Exp. Ther. 265: 1280-1291. [Abstract/Free Full Text]
  50. Garcia, M. L., R. S. Slaughter, V. F. King, G. J. Kaczorowski. 1988. Inhibition of sodium-calcium exchange in cardiac sarcolemmal membrane vesicles. II. Mechanism of inhibition by bepridil. Biochemistry 27: 2410-2415. [Medline]
  51. Vernhet, L., J. Y. Petit, F. Lang. 1997. An anti-inflammatory benzamide derivative inhibits the protein kinase C (PKC)-dependent pathway of ERK2 phosphorylation in murine macrophages. J. Pharmacol. Exp. Ther. 283: 358-365. [Abstract/Free Full Text]
  52. Matsumoto, E., M. Hatanaka, M. Bohgaki, S. Maeda. 2006. PKC pathway and ERK/MAPK pathway are required for induction of cyclin D1 and p21Waf1 during 12-o-tetradecanoylphorbol 13-acetate-induced differentiation of myeloleukemia cells. Kobe J. Med. Sci. 52: 181-194. [Medline]
  53. Perillo, B., A. Sasso, C. Abbondanza, G. Palumbo. 2000. 17beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence. Mol. Cell Biol. 20: 2890-2901. [Abstract/Free Full Text]
  54. Orrenius, S., B. Zhivotovsky, P. Nicotera. 2003. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 4: 552-565. [Medline]
  55. Wu, T. W., J. M. Wang, S. Chen, R. D. Brinton. 2005. 17beta-Estradiol induced Ca2+ influx via L-type calcium channels activates the Src/ERK/cyclic-AMP response element binding protein signal pathway and Bcl-2 expression in rat hippocampal neurons: a potential initiation mechanism for estrogen-induced neuroprotection. Neuroscience 135: 59-72. [Medline]
  56. Grimaldi, C. M., J. Cleary, A. S. Dagtas, D. Moussai, B. Diamond. 2002. Estrogen alters thresholds for B cell apoptosis and activation. J. Clin. Invest. 109: 1625-1633. [Medline]
  57. Garcia-Segura, L. M., P. Cardona-Gomez, F. Naftolin, J. A. Chowen. 1998. Estradiol upregulates Bcl-2 expression in adult brain neurons. Neuroreport 9: 593-597. [Medline]
  58. Somai, S., M. Chaouat, D. Jacob, J. Y. Perrot, W. Rostene, P. Forgez, A. Gompel. 2003. Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int. J. Cancer 105: 607-612. [Medline]
  59. Wei, M. C., W. X. Zong, E. H. Cheng, T. Lindsten, V. Panoutsakopoulou, A. J. Ross, K. A. Roth, G. R. MacGregor, C. B. Thompson, S. J. Korsmeyer. 2001. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730. [Abstract/Free Full Text]
  60. Nuessler, V., O. Stötzer, E. Gullis, R. Pelka-Fleischer, A. Pogrebniak, F. Gieseler, W. Wilmanns. 1999. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia 13: 1864-1872. [Medline]
  61. Rees, R. C., H. Parry. 1992. Macrophages in tumor immunity. C. E. Lewis, and J. O’D. McGee, eds. The Macrophage 315 Oxford University Press, New York, NY.



This article has been cited by other articles:


Home page
 FASEB J.Home page
A. Maselli, P. Matarrese, E. Straface, S. Canu, F. Franconi, and W. Malorni
Cell sex: a new look at cell fate studies
FASEB J, April 1, 2009; 23(4): 978 - 984.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
S. Renolleau, S. Fau, and C. Charriaut-Marlangue
Gender-Related Differences in Apoptotic Pathways After Neonatal Cerebral Ischemia
Neuroscientist, February 1, 2008; 14(1): 46 - 52.
[Abstract] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Subramanian, M.
Right arrow Articles by Shaha, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Subramanian, M.
Right arrow Articles by Shaha, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS